Equities research analysts expect Thermo Fisher Scientific Inc (NYSE:TMO) to report earnings per share (EPS) of $2.67 for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have provided estimates for Thermo Fisher Scientific’s earnings, with estimates ranging from $2.64 to $2.79. Thermo Fisher Scientific reported earnings per share of $2.41 during the same quarter last year, which indicates a positive year over year growth rate of 10.8%. The company is expected to issue its next earnings report on Tuesday, January 30th.
On average, analysts expect that Thermo Fisher Scientific will report full year earnings of $9.36 per share for the current fiscal year, with EPS estimates ranging from $9.33 to $9.49. For the next financial year, analysts forecast that the firm will report earnings of $10.55 per share, with EPS estimates ranging from $10.40 to $10.98. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that that provide coverage for Thermo Fisher Scientific.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business had revenue of $5.12 billion during the quarter, compared to analysts’ expectations of $5.03 billion. During the same quarter in the prior year, the business posted $2.03 earnings per share. Thermo Fisher Scientific’s revenue was up 13.9% compared to the same quarter last year.
Several equities research analysts recently weighed in on TMO shares. Barclays PLC reaffirmed an “overweight” rating and set a $200.00 price objective (up previously from $190.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 17th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research report on Thursday, July 20th. Bank of America Corporation reaffirmed a “buy” rating and set a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research report on Friday, July 21st. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, BidaskClub cut shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $205.71.
ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/11/11/2-67-earnings-per-share-expected-for-thermo-fisher-scientific-inc-tmo-this-quarter.html.
In other news, VP Seth H. Hoogasian sold 4,140 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the completion of the transaction, the vice president now owns 25,518 shares of the company’s stock, valued at $4,537,100.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director C Martin Harris sold 360 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total value of $65,149.20. Following the completion of the transaction, the director now directly owns 5,312 shares of the company’s stock, valued at approximately $961,312.64. The disclosure for this sale can be found here. Insiders sold 22,738 shares of company stock valued at $4,021,512 in the last ninety days. 0.49% of the stock is currently owned by insiders.
Institutional investors have recently added to or reduced their stakes in the company. Proficio Capital Partners LLC increased its stake in shares of Thermo Fisher Scientific by 71.5% in the first quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Chicago Partners Investment Group LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at approximately $108,000. Cribstone Capital Management LLC increased its position in Thermo Fisher Scientific by 8.7% during the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 50 shares during the period. Sharkey Howes & Javer increased its position in Thermo Fisher Scientific by 1.0% during the 1st quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after purchasing an additional 7 shares during the period. Finally, Shine Investment Advisory Services Inc. acquired a new stake in Thermo Fisher Scientific during the 2nd quarter valued at approximately $113,000. 83.66% of the stock is owned by institutional investors.
Thermo Fisher Scientific (NYSE TMO) traded down $5.71 on Monday, reaching $186.18. 3,009,200 shares of the company traded hands, compared to its average volume of 1,551,175. Thermo Fisher Scientific has a 1-year low of $139.07 and a 1-year high of $201.20. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81. The company has a market capitalization of $76,947.01, a PE ratio of 21.09, a price-to-earnings-growth ratio of 1.76 and a beta of 1.08.
The business also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be issued a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.19%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.